Extracellular miRNA biomarkers in neurologic disease: is cerebrospinal fluid helpful?

Biomark Med. 2021 Oct;15(15):1377-1388. doi: 10.2217/bmm-2021-0092. Epub 2021 Sep 13.

Abstract

Aim: The aim of our work is to aggregate data from publications of cerebrospinal fluid extracellular miRNA to identify candidate diagnostic biomarkers, and those warranting further study. Materials & methods: Data were pooled from nine studies, encompassing 864 patients across 16 diseases. Unsupervised clustering grouped patients by a broad category of diseases. Results & conclusion: Compared with healthy controls, in patients with Alzheimer's disease, hsa-miR-767-5p was overexpressed (p < 0.001) and in patients with Huntington's disease, hsa-miR-361-3p was underexpressed (p < 10-4). We also define a subset of extracellular miRNA as candidate biomarkers that are robustly detected across patients, studies and diseases; thereby, warranting further study.

Keywords: Alzheimer’s disease; Parkinson’s disease; diagnostics; neurology; translational medicine.

MeSH terms

  • Adult
  • Aged
  • Alzheimer Disease / cerebrospinal fluid
  • Alzheimer Disease / diagnosis
  • Alzheimer Disease / genetics
  • Amyotrophic Lateral Sclerosis / cerebrospinal fluid
  • Amyotrophic Lateral Sclerosis / diagnosis
  • Amyotrophic Lateral Sclerosis / genetics
  • Biomarkers / cerebrospinal fluid*
  • Biomarkers / metabolism
  • Cluster Analysis
  • Female
  • Gene Expression Profiling / methods*
  • Gene Regulatory Networks / genetics*
  • Humans
  • Huntington Disease / cerebrospinal fluid
  • Huntington Disease / diagnosis
  • Huntington Disease / genetics
  • Male
  • MicroRNAs / cerebrospinal fluid*
  • MicroRNAs / genetics
  • Middle Aged
  • Neurodegenerative Diseases / cerebrospinal fluid*
  • Neurodegenerative Diseases / diagnosis
  • Neurodegenerative Diseases / genetics
  • Parkinson Disease / cerebrospinal fluid
  • Parkinson Disease / diagnosis
  • Parkinson Disease / genetics

Substances

  • Biomarkers
  • MicroRNAs